Blood-Brain Barrier Disruption

John M. McGregor, Nancy Doolittle, Emily Youngers, Susan D. Bell, Edward A. Neuwelt

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Delivery of therapeutic molecules into the central nervous system (CNS) is hampered by the blood-brain barrier (BBB). Various methods have been developed to allow passage of agents into the CNS, and translational studies in BBB research attempt to evaluate toxicity and efficacy of global CNS delivery of chemotherapeutics. Osmotic BBB disruption is a safe and effective means of delivering agents to the CNS when clinicians practice strict adherence to safety guidelines. The studies that have been conducted by participating BBB Consortium institutions have paved the way for safe delivery of agents to the CNS, with minimum local and systemic toxicities. Advances in the two-compartment model concept of pharmacokinetics suggest options for increasing therapeutic benefit and mitigating systemic toxicities for agents delivered to the CNS. The concept has proved beneficial in situations where drugs can be used in combination and with proper timing to act as chemoprotectants. Further development of BBB techniques will improve monitoring of therapeutic responses, as suggested by iron nanoparticles.

Original languageEnglish (US)
Title of host publicationNervous System Drug Delivery
Subtitle of host publicationPrinciples and Practice
PublisherElsevier
Pages193-208
Number of pages16
ISBN (Electronic)9780128139981
ISBN (Print)9780128139974
DOIs
StatePublished - Jun 25 2019

Keywords

  • Blood-brain barrier
  • Brain tumor imaging
  • Brain tumor therapy
  • Chemotherapy
  • Iron nanoparticles
  • Mannitol
  • Osmotic disruption

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Blood-Brain Barrier Disruption'. Together they form a unique fingerprint.

Cite this